BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 216
- Registration Number
- NCT04817007
- Locations
- 🇫🇷
Local Institution - 0010, Villejuif, France
🇺🇸Local Institution - 0069, Newport Beach, California, United States
🇺🇸Local Institution - 0090, Lake Mary, Florida, United States
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 632
- Registration Number
- NCT04810078
- Locations
- 🇷🇴
Local Institution - 0040, Cluj-Napoca, Romania
🇷🇴Local Institution - 0016, Craiova, Romania
🇷🇴Local Institution - 0002, Cluj-Napoca, Romania
A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 825
- Registration Number
- NCT04794010
- Locations
- 🇩🇪
Local Institution - 0001, Leipzig, Germany
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Plaque Psoriasis
- Interventions
- Other: Placebo matching deucravacitinib
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 153
- Registration Number
- NCT04772079
- Locations
- 🇵🇱
Local Institution - 0011, Krakow, Poland
🇧🇷Centro de Pesquisas da Clínica IBIS, Salvador, Bahia, Brazil
🇦🇷Instituto de Neumonologia Y Dermatologia, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT04766892
- Locations
- 🇺🇸
Local Institution - 0014, Miami, Florida, United States
🇺🇸Local Institution - 0011, Tucson, Arizona, United States
🇺🇸Local Institution - 0005, Los Angeles, California, United States
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
- Conditions
- Nonalcoholic Fatty Liver Disease
- Interventions
- Other: Placebo matching BMS-963272
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT04766476
- Locations
- 🇺🇸
Arizona Liver Health - Tucson, Tucson, Arizona, United States
🇺🇸Pinnacle Clinical Research - Austin, Austin, Texas, United States
🇺🇸Local Institution, San Antonio, Texas, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT04763226
- Locations
- 🇺🇸
Local Institution - 0001, Lenexa, Kansas, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Biological: BMS-986326Other: Placebo matching BMS-986326Biological: Multiple Ascending Dose SCOther: Multiple Ascending Dose Placebo
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 88
- Registration Number
- NCT04736134
- Locations
- 🇩🇪
Local Institution - 0001, Berlin, Germany
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
- Conditions
- High-grade GliomaMiscellaneous Brain TumorsMiscellaneous Solid TumorsMedulloblastomaEpendymomaEwing SarcomaLeukemia and LymphomaNeuroblastomaRelapsed, Refractory Malignant NeoplasmsRhabdomyosarcoma
- Interventions
- Biological: NivolumabBiological: NKTR-214
- First Posted Date
- 2021-01-29
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT04730349
- Locations
- 🇦🇺
Local Institution - 0003, Perth, Western Australia, Australia
🇫🇷Local Institution - 0015, Paris, France
🇪🇸Local Institution - 0059, Sevilla, Spain
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT04702880
- Locations
- 🇺🇸
Local Institution - 0060, Cincinnati, Ohio, United States
🇺🇸Local Institution - 0002, Durham, North Carolina, United States
🇦🇺Local Institution - 0004, Murdoch, Western Australia, Australia